Although the 62nd American Society of Hematology meetings did not officially kick off until this morning, I had the opportunity to attend three of the pre-ASH Symposiums held yesterday. This is one advantage of the virtual platform that I appreciate. Each of the symposiums offered informative panel discussions with some of the best myeloma doctors […]
Friday is symposium day at the 62nd ASH Annual Meeting. These symposia are precursors to the official ASH meeting. Each is generally 2-3 hours long. At the symposium hosted by Dr. Brian G.M. Durie and the International Myeloma Foundation, they presented actual patient case-studies, asking the panel, and the audience, how they would treat these […]
Friday, the International Myeloma Foundation held its annual symposium at #ASH20. This has always been a highlight for me as it’s a primer of what’s to come with all the abstracts throughout the weekend. This CME-certified webinar featuring discussion of patient-case studies and key clinical trial data by renowned clinical experts providing their perspectives on […]
Thanks to my dexamethasone today, I’m writing this in the wee hours of Saturday morning, and the All-Virtual 62nd American Society of Hematology (ASH) Meeting and Exposition kicks off in and few hours. It will include many abstracts (research presentations) about the future of multiple myeloma treatments. But even before ASH begins, the International Myeloma […]
The Friday before the official start of ASH is always considered Symposium day. However, even before Friday, there are typically more meetings of different groups. And even though this year’s 62nd American Society of Hematology (ASH) meeting is virtual, there’s no exception to pre-Symposium day meetings and I’ve attended three already. The first was a […]
